Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC, designates this live activity for a maximum of 26.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 26.0 Contact Hours.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 4.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
This activity provides Category I CME and self-assessment credits toward Part 2 of the ABS MOC Program. For more information, please visit http://www.absurgery.org
The 36th Annual Miami Breast Cancer Conference®(MBC) is supported by educational grants from AbbVie Inc., AstraZeneca, Celgene Corporation, Daiichi Sankyo, Inc., Eisai, Genentech, Inc., Genomic Health, Inc., Lilly, Merck Sharp & Dohme Corp, Novartis Pharmaceuticals Corporation, Pacira Pharmaceuticals, Inc., Pfizer, Puma Biotechnology, Inc., and Seattle Genetics, Inc.
For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.
Dr. Gregory Stock
Saturday, March 9, 2019
Dr. Gregory Stock, a biotech entrepreneur, bioethicist, best-selling author and public communicator is a leading authority on the broad impacts of genomic and other advanced technologies in the life sciences. Currently he is the Co-Director of the Mount Sinai Precision Wellness Center. He founded the influential Program on Medicine, Technology and Society at UCLA’s School of Medicine in 1997 and served as its director for ten years while leading a broad effort to explore critical technologies poised to impact humanity’s future and reshape medical science and healthcare. Through a series of high-profile symposia, lectures, and media appearances, Stock has catalyzed broad public debate about the social and public policy implications of today’s revolution in molecular genetics and bioinformatics, and about how most effectively to translate progress in basic science into improved therapeutics and healthcare.
Dr. Stock is a longtime advocate for aggressive biomedical research funding and cautious regulatory policy. In 2003, he co-founded Signum Biosciences, a Princeton University spinoff created to develop a new class of anti-inflammatory signal-transduction molecules to combat neurodegeneration. He served as the CEO of Signum for 7 years, directing efforts to develop a therapeutic for Alzheimer’s and related anti-inflammatory cosmeceuticals and nutraceuticals. In 2010, he co-founded Ecoeos, a personalized-health company that developed the first genetic test for susceptibility to mercury toxicity. Stock served as CEO and CSO of Ecoeos until 2014.
Dr. Stock has been an invited speaker to many academic, government and business conferences. He sits on the editorial boards of The Journal of Evolution and Technology, and Rejuvenation Research. Stock has been profiled in the Wall Street Journal, New York Times, MIT Tech Review and Lancet. He makes regular appearances on television and radio, including CNN, PBS, NPR, Bloomberg, and the BBC and has been in dozens of one-on-one healthcare and policy debates with Francis Fukuyama, Jeremy Rifkin, Leon Kass, Daniel Callahan, Ray Kurzweil, Bill McKibben, George Annas and other prominent figures.
Dr. Stock’s book, Redesigning Humans: Our Inevitable Genetic Future with Houghton Mifflin won the Kistler Book Prize for Science books and was nominated for a Wired Rave Award. Among his other books are Engineering The Human Germline: An Exploration of the Science and Ethics of Altering the Genes We Pass to Our Children with Oxford University Press, Metaman: The Merging of Humans and Machines into a Global Superorganism with Simon & Schuster, and his best seller, The Book of Questions with Workman Press, which has sold 2 1/2 million copies and been translated into 18 languages. It is now in its 77th printing. Sequels to that book include The Book of Questions: Business, Politics, and Ethics, The Book of Questions: Love and Sex, and The Kids’ Book of Questions. Stock is now working on a new book, On the Cusp: The Future of Healthcare and Medicine, to examine the disruptive, technology-driven transformation of Medicine that is rapidly approaching.
Gregory Stock serves on the California Advisory Committee on Stem Cells and Reproductive Cloning. He also serves on the boards of Signum Biosciences, Nutralogix, and Napo Pharmaceuticals, a private pharmaceutical company with a fast-tracked drug for diarrhea associated with HIV retroviral therapy. He has a doctorate in Biophysics from Johns Hopkins University and an MBA from Harvard University.
Saturday, March 9, 2019
Stephanie Seban is an 8-year metastatic breast cancer (MBC) thriver, blogger, and wellness advocate. Despite a misdiagnosis and her ongoing journey with MBC, she finds joy and purpose in inspiring others by sharing her experiences and has become involved in multiple philanthropic works and projects.
She learned quickly that there is an unfortunate lack of resources and support for young women with metastatic disease. As a result, she has made it her life’s mission and purpose to advocate for other young women by providing hope and thriving by example.
She is currently co-authoring a book, The Thrivers Guide (https://thethriversguide.com/), in order to share her knowledge and experiences living with MBC.
May 30, 2019
May 31, 2019
Medical Crossfire®: Personalizing Care for Multiple Myeloma Patients: Current and Future Sequencing Strategies
May 31, 2019
May 31, 2019
May 31, 2019